Abstract
Much attention has been paid in initial biochemical studies on the ability of indoleamine 2,3-dioxygenase to use superoxide as substrate to cleave tryptophan to N-formyl kynurenine. This ability, however, is limited to the ferric form of the enzyme only, whereas the ferrous form requires oxygen rather than superoxide as substrate. As long as the enzyme is held in the ferrous form, high yield formation of product proceeds from the ferrous oxygen tryptophan ternary complex without the participation of superoxide. Enzyme assays in homogenates are carried out in presence of Methylene Blue, ascorbate and catalase. Ascorbate can be replaced by other reductants like e.g. tetrahydrobiopterin. Experiments with alteration of intracellular tetrahydrobiopterin concentrations in intact interferon-gamma treated cells clearly showed that tetrahydrobiopterin is not required for the indoleamine 2,3-dioxygenase reaction. In homogenates of interferongamma treated T-24 cells, substrates of xanthine oxidase did not stimulate the indoleamine 2,3-dioxygenase reaction, nor did allopurinol inhibit the reaction, nor did superoxide dismutase alter indoleamine 2,3-dioxygenase activity irrespective of the reductant used. From these experiments we concluded that molecular oxygen rather than superoxide is used in cell homogenates by indoleamine 2,3- dioxygenase to cleave L-tryptophan. A detailed analysis of available reports on oxygen and superoxide utilization by indoleamine 2,3- dioxygenase gives a comprehensive picture that the enzyme uses oxygen bound to the ferrous enzyme for cleavage of tryptophan, that the enzyme needs to be held by reductants in the ferrous state in enzyme incubations, and that superoxide is one of the reductants capable performing this reduction.
Keywords: Indoleamine-pyrrole 2,3-dioxygenase, tetrahydrobiopterin, oxygen, superoxide, lavinmononucleotide, superoxide dismutase, tryptophan, interferon-gamma
Current Drug Metabolism
Title: Substrate and Cofactor Requirements of Indoleamine 2,3-Dioxygenase in Interferon-Gamma-Treated Cells: Utilization of Oxygen Rather Than Superoxide
Volume: 8 Issue: 3
Author(s): Ernst R. Werner and G. Werner-Felmayer
Affiliation:
Keywords: Indoleamine-pyrrole 2,3-dioxygenase, tetrahydrobiopterin, oxygen, superoxide, lavinmononucleotide, superoxide dismutase, tryptophan, interferon-gamma
Abstract: Much attention has been paid in initial biochemical studies on the ability of indoleamine 2,3-dioxygenase to use superoxide as substrate to cleave tryptophan to N-formyl kynurenine. This ability, however, is limited to the ferric form of the enzyme only, whereas the ferrous form requires oxygen rather than superoxide as substrate. As long as the enzyme is held in the ferrous form, high yield formation of product proceeds from the ferrous oxygen tryptophan ternary complex without the participation of superoxide. Enzyme assays in homogenates are carried out in presence of Methylene Blue, ascorbate and catalase. Ascorbate can be replaced by other reductants like e.g. tetrahydrobiopterin. Experiments with alteration of intracellular tetrahydrobiopterin concentrations in intact interferon-gamma treated cells clearly showed that tetrahydrobiopterin is not required for the indoleamine 2,3-dioxygenase reaction. In homogenates of interferongamma treated T-24 cells, substrates of xanthine oxidase did not stimulate the indoleamine 2,3-dioxygenase reaction, nor did allopurinol inhibit the reaction, nor did superoxide dismutase alter indoleamine 2,3-dioxygenase activity irrespective of the reductant used. From these experiments we concluded that molecular oxygen rather than superoxide is used in cell homogenates by indoleamine 2,3- dioxygenase to cleave L-tryptophan. A detailed analysis of available reports on oxygen and superoxide utilization by indoleamine 2,3- dioxygenase gives a comprehensive picture that the enzyme uses oxygen bound to the ferrous enzyme for cleavage of tryptophan, that the enzyme needs to be held by reductants in the ferrous state in enzyme incubations, and that superoxide is one of the reductants capable performing this reduction.
Export Options
About this article
Cite this article as:
Werner R. Ernst and Werner-Felmayer G., Substrate and Cofactor Requirements of Indoleamine 2,3-Dioxygenase in Interferon-Gamma-Treated Cells: Utilization of Oxygen Rather Than Superoxide, Current Drug Metabolism 2007; 8 (3) . https://dx.doi.org/10.2174/138920007780362482
DOI https://dx.doi.org/10.2174/138920007780362482 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Complement 3 Receptor Expression in Individuals with Type 2 Diabetes
Recent Patents on Anti-Infective Drug Discovery Synthesis of Metallothionein-Mimic Decapeptides with Heavy Atom Signaling Properties
Combinatorial Chemistry & High Throughput Screening Editorial [Hot topic: Natural Antioxidants and their Derivatives:Biology and Clinical Application (Guest Editors: Thea Magrone, Yoshio Kumazawa & Emilio Jirillo)]
Current Topics in Medicinal Chemistry Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Role of AGEs in Diabetic Nephropathy
Current Pharmaceutical Design Drug Metabolism and Pharmacokinetics in Support of Drug Design
Current Pharmaceutical Design Nitric Oxide Signaling and the Cross Talk with Prostanoids Pathways in Vascular System
Medicinal Chemistry New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer
Current Drug Targets Mesothelioma - Epidemiology and Management
Current Respiratory Medicine Reviews Adenosine Receptors: New Therapeutic Targets for Inflammation in Diabetic Nephropathy
Inflammation & Allergy - Drug Targets (Discontinued) The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy
Current Pharmaceutical Biotechnology Clozapine Induced Eosinophilia in a Case of Schizoaffective Disorder
Current Psychopharmacology HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview
Current Drug Metabolism The Emerging Role of the Histamine H4 Receptor in Anti-inflammatory Therapy
Current Topics in Medicinal Chemistry Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Progress in Drug Treatment of Cerebral Edema
Mini-Reviews in Medicinal Chemistry Oxidative Stress, HDL and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update
Current Cancer Drug Targets